USPTO serial 79156199
V VALNEVA
Reviewed by CopyMark Law Group
Reg. 4774813Status 706Registered
- Filing date
- Status date
- Registration date
- Jul 21, 2015
- Examiner
- HOLTZ, ALLISON
- Law office
- Historical data usage
What this means
This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.
Need help with V VALNEVA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
F-69007 Lyon, FR
F-69007 Lyon, FR
Saint Herblain, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Christina M. Licursi
Christina M. Licursi Wolf, Greenfield & Sacks, P.C.600 Atlantic AvenueBoston, MA 02210United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products, namely, fungicides, herbicides, insecticides and parasiticides for use in industry, science as well as in agriculture; molecules from bio technologies, namely, proteins in raw material for scientific and medical research; cells for scientific, laboratory or medical research; cell lines for scientific and medical research; nucleic acids for laboratory use; proteins for industrial use; recombinant proteins for industrial use; biomedical compounds, namely, peptides substrates; peptide antigens used in analyzing and detecting certain toxins for research, clinical, medical laboratory use; Biochemical preparations derived from blood serum for use in scientific and medical research; Bio chemicals, namely, antibodies and fragments thereof for in vitro scientific or research use, Chemicals for use in biotechnological product development; cultures of microorganisms other than for medical and veterinary use; viruses, cells, biological, bacteriological or viral preparations, other than for nucleic acids for scientific, laboratory, or medical research | ACTIVE | — |
| 005 | Pharmaceutical products for human and veterinary use for the treatment of auto immune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; medical, biological, biotechnological, protein, virological, immunological, bacteriological, chemical, enzymatic and pharmaceutical preparations for medical and veterinary use; medical, biological, biotechnological, protein, virological, immunological, bacteriological, chemical, enzymatic and pharmaceutical products, namely, preparation of encapsulated cells which release antibodies for medical and veterinary use; diagnostic products, namely, diagnostic preparations for use in human, veterinary medicine and pharmaceutical use; cell, microorganism or virus cultures for medical and veterinary use; adjuvants for medical or veterinary use; antibiotics, vaccines, viruses, viral vectors, nucleic acids, proteins, recombinant proteins, peptides, peptide antigens, blood serum, antibodies and fragments thereof, and cells for medical, pharmaceutical and veterinary use; viral substances, immunological substances, bacterial substances, enzyme substances used for human and veterinary medicine; diagnostic kits consisting primarily of antibodies and fragments thereof for use in disease testing; diagnostic kits primarily of antibodies and antibody fragments for use in disease testing | ACTIVE | — |
| 042 | Scientific research services for medical purposes in the fields of auto immune diseases, inflammation, cancer, infectious diseases, diseases, diseases of the central nervous system, cardiovascular diseases, neurodegenerative and chronic diseases; scientific research for medical, pharmaceutical and veterinary purposes in the fields of auto immune diseases, inflammation, cancer, infectious diseases, diseases of the central nervous systems, cardiovascular diseases, neurodegenerative and chronic diseases; scientific and industrial research, in particular in the fields of biology, cellular and molecular biology, biotechnology, bacteriology, immunology, genetics, gene study, medicine, pharmacology, virology, chemistry; scientific research relating to vaccines, antibiotics and immunological products for human and veterinary use; research and development of new products for others; testing and evaluations of the goods of others to assure compliance with industry standards in the scientific, medical and veterinary fields; research and development of new products for human and veterinary use; scientific research, namely, preparation of scientific experts opinion reports in the scientific, medical and veterinary fields; development and design of laboratory instruments for scientific and industrial research, in particular to obtain and prepare cells, cell lines, viruses, proteins, animal and human materials; development of vaccines, antibiotics and immunological products for human and veterinary use; scientific and technological services, namely, diagnostic and prognostic analyses in the fields of cells, cell lines, animal and human materials, microorganisms, molecules for scientific purposes; scientific research, namely, preparation of scientific expert opinions reports | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VALNEVA
- Other trademarks owned by VALNEVA
- Other trademarks owned by VALNEVA
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named V VALNEVA
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | LIMN | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED | — |
| Jul 9, 2026 | RHRD | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED | — |
| Aug 12, 2025 | NA71 | NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED | — |
| Aug 12, 2025 | 71AG | REGISTERED-SEC.71 ACCEPTED | — |
| Jul 29, 2025 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| May 12, 2025 | ES71 | TEAS SECTION 71 RECEIVED | — |
| Jul 21, 2024 | REM4 | COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED | — |
| Jun 7, 2024 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Oct 15, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 24, 2021 | NA75 | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | — |
| Aug 24, 2021 | C75A | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | — |
| Aug 24, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 13, 2021 | ES75 | TEAS SECTION 71 & 15 RECEIVED | — |
| Jul 21, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 26, 2019 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 13, 2018 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Dec 22, 2016 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 8, 2016 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Dec 9, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Dec 9, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 21, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 21, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 5, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 5, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 2, 2015 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Apr 15, 2015 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Apr 15, 2015 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Apr 15, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 31, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 30, 2015 | ALIE | ASSIGNED TO LIE | — |
| Mar 12, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 12, 2015 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 12, 2015 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2015 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2015 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 23, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 23, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 23, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 4, 2015 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 15, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 15, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 12, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 12, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 11, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 8, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 8, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 4, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |